US6700024010 - Common Stock
4.88 +0.9 (+22.61%)
Premarket: 4.9798 +0.1 (+2.05%)
NASDAQ:NVAX (2/22/2024, 7:00:56 PM)Premarket: 4.9798 +0.1 (+2.05%)
Find more stocks on Nasdaq
Find more stocks on the USA
Find competitors from the same sector on the USA
Find competitors from the same industry on the USA
Find stocks with similar TA and Setup ratings on the USA
Find stocks with similar Fundamental rating on the USA
Find the competitors with the best technical ratings on the USA
Find the competitors with the best technical and setup ratings on the USA
Find the competitors with the best fundamentals on the USA
Find the competitors with the best valuation on the USA
Find the competitors with the best dividend on the USA
Find the competitors with the best analyst ratings on the USA
Novavax, Inc. Is a biotechnology company, which engages in the discovery, development, and commercialization of recombinant vaccines. The company is headquartered in Gaithersburg, Maryland and currently employs 1,992 full-time employees. The firm has developed and begun commercialization of its lead product, NVX-CoV2373, which is a COVID-19 vaccine. NVX-CoV2373 has received approval, interim authorization, provisional approval, conditional marketing authorization (CMA), and emergency use authorization (EUA) from multiple regulatory authorities globally for both adult and adolescent populations as a primary series and for both homologous and heterologous booster indications in over 40 countries. The company is also developing an influenza vaccine candidate, quadrivalent nanoparticle influenza vaccine (qNIV); a COVID-19-Influenza Combination (CIC) vaccine candidate; and additional vaccine candidates, including a COVID-19 variant strain-containing monovalent or bivalent formulation. In addition, its other areas of focus include respiratory syncytial virus (RSV) and malaria.
700 Quince Orchard Road
Gaithersburg MARYLAND 20878
CEO: Stanley C. Erck
Let's take a look at the stocks that are in motion in today's session.
Novavax (NVAX) stock soars as the company settles a dispute with Gavi over COVID vaccine deliveries, agreeing to pay at least $475M by 2028. Read more here.
DoorDash stock is rising higher on Thursday after Morgan Stanley upgraded DASH shares and increased their price target for them.
Rivian stock is falling hard on Friday as RIVN investors react to a warning from Morgan Stanley and a weak EV production guidance for 2024.
Thursday's session: gap up and gap down stocks
Here you can normally see the latest stock twits on NVAX, but your cookie settings prevent this from loading. You can edit your cookie settings in our cookie consent dialog.